Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study, Edwin Lam, Luis Eraso, Taki Galanis, Walter K. Kraft, Geoffrey Ouma, Lynda Thomson, Eugene Viscusi, Douglas Stickle, Jerald Z. Gong, Suzanne Adams, Geno Merli
Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study, Edwin Lam, Luis Eraso, Taki Galanis, Walter K. Kraft, Geoffrey Ouma, Lynda Thomson, Eugene Viscusi, Douglas Stickle, Jerald Z. Gong, Suzanne Adams, Geno Merli
Department of Pharmacology and Experimental Therapeutics Posters
Primary Objective
- Estimate the proportion of patients who achieve a plasma apixaban concentration of/mL following at least 48 hours of discontinuation prior to surgery or invasive procedure
Secondary Objective
- Perioperative and follow up arterial or venous thromboembolic events, major bleeding, clinically significant non-major bleeding complications. Correlation of apixaban anti-Factor Xa (FXa) activity and plasma apixaban concentrations at pre-admission and prior to surgery